Agenus


William Blair Maintains Outperform On Agenus Following Positive Phase III Data From Shingles Vaccine

William Blair analyst John Sonnier maintained an Outperform rating on Agenus (NASDAQ:AGEN), as its partner GlaxoSmithKline (NYSE:GSK) reported positive Phase III results with an investigational …

MLV Reiterates Buy On Agenus Following Positive Outcome Of Phase 3 Study Of GSK Shingles Vaccine

In a research report sent to investors today, MLV analyst George Zavoico reiterated a Buy rating on Agenus (NASDAQ:AGEN) with a $6.00 price …

Maxim Reiterates Buy On Agenus Following 3Q14 Update; Sees 183% Upside For The Stock

In a research report released today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Agenus (NASDAQ:AGEN) with a price target of $9.00, …

Maxim Reiterates Buy On Agenus As Paradigm Shift Is Taking Hold In Immune-Based Therapeutics

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Agenus (NASDAQ:AGEN) with a $9 price target, which represents …

Maxim Keeps ‘Buy’ On Agenus Following Phase 2 Trial Data From HerpV

In a research note issued today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Agenus Inc. (AGEN) and a price target of $11, after AGEN announced the final data set …